User-centred Assistive System for Arm Functions in Neuromuscular Subjects | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
recruiting

User-centred Assistive System for Arm Functions in Neuromuscular Subjects

key information

study id #: NCT03127241

condition: Muscular Dystrophies, Duchenne Muscular Dystrophy, Limb-Girdle Type 2 Muscular Dystrophy, Becker Muscular Dystrophy

status: recruiting

purpose:

Restore a lost function is a special experience for people affected by neuromuscular evolutive diseases. “From the patient’s point of view improvement is measured by regaining lost abilities,-by being able to do something -anything-today I couldn’t do yesterday “. Upper limb pain, stiffness and activity limitations have a crucial role in reducing patients’ autonomy and worsening quality of life. Real users’ needs have been identified thought several workshops, and even if the commercial products might assure a benefit to some users and meet most of their requirements, so far a validation of the use of such devices by people with neuromuscular disease is missing. We aim at field-testing the improvement in arm functions provided by the use of some commercial devices and assessing their impact to users’ quality of life and independence. This step is essential to assure a widespread accessibility to these devices for most of the potential users, possibly providing health providers with direction and guidance towards Health Technology Assessment. Clinical Trial design – The study proposes on-field validation of JAECO WREX, passive antigravity exoskeleton; and Armon Ayura, motorized arm exoskeleton for gravity compensation in a randomized controlled trial with crossover design. The clinical study will is multi-centric, involving both MEDEA and VALDUCE, and received the Ethical Committee approval.

intervention: Assistive device (Armon Ayura) test, Assistive device (Jaeco Wrex) test

mechanism of action: No pharmaceutical intervention

results: https://clinicaltrials.gov/ct2/show/results/NCT03127241

last updated: March 13, 2019

study details

start date: June 16, 2017

estimated completion: October 31, 2019

phase of development: N/A

size / enrollment: 38

primary outcomes:

  • Performance of the Upper Limb (PUL) scale [ Time Frame: T0 (baseline); T1 (after 3-days short training with device 1); T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point) ]
    The PUL includes 22 items with an entry item to define the starting functional level, and 21 items subdivided into shoulder level (4 items), middle level (9 items) and distal level (8 items) dimension. For weaker patients a low score on the entry item means high level items do not need to be performed. Scoring options vary across the scale between 0-1 to 0-6 according to performance. Each dimension can be scored separately with a maximum score of 16 for the shoulder level, 34 for the middle level, and 24 for the distal level . A total score can be achieved by adding the three level scores (max total score 74).

secondary outcomes:

  • Motor Function Measures scale (MFM) [Time Frame: T0 (baseline); T1 (after 3-days short training with device 1); T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point)]
    MFM is a quantitative scale that makes it possible to measure the functional motor abilities of a person affected by a neuromuscular disease.
  • Brooke scale [Time Frame: T0 (baseline); T1 (after 3-days short training with device 1); T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point)]
    The Brooke scale was designed to assess the upper extremity function. The grades of the Brooke scale range from 1 to 6; 1 means that the subject can elevate their arms full range to the head with the arms straight; while 2 means that the shoulder strength is insufficient to elevate their arms and the subject needs to flex the elbow to elevate the arms; in grades 3 and 4, the subject is unable to elevate the shoulders but can raise hands to the mouth with or without weight respectively; grade 5 refers to the subject being unable to raise hands to the mouth and only some hand movement exists, while grade 6 refers to no useful function of hands.
  • ABILHAND [Time Frame: T0 (baseline); T1 (after 3-days short training with device 1); T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point)]
    a measure of manual ability to manage daily activities that require the use of the upper limbs, whatever the strategies involved
  • PedsQL [ Time Frame: T0 (baseline); T2 (after 2-weeks home use of device 1 - primary assessment point); T4 (after 2-weeks home use of device 2 - secondary assessment point) ]
    Neuromuscular module: composed of 25 items comprising 3 dimensions, i.e. about my neuromuscular disease (1-17); communication (1-3); and about our faily resources (1-5) Multidimensional Fatigue module: composed of 18 items comprising 3 dimensions, i.e. general fatigue (1-6); sleep/rest fatigue (1-6); and cognitive fatigue (1-6).
  • PROMIS FATIGUE Short Form [Time Frame: T0 (baseline); T2 (after 2-weeks home use of device 1 - primary assessment point); T4 (after 2-weeks home use of device 2 - secondary assessment point)]
    The PROMIS Fatigue instruments evaluate a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The Fatigue short form is universal rather than disease-specific. It assesses fatigue over the past seven days.
  • Personal Adjustment and Role Skills Scale (PARS) III [ Time Frame: T0 (baseline); T2 (after 2-weeks home use of device 1 - primary assessment point); T4 (after 2-weeks home use of device 2 - secondary assessment point) ]
    PARS III to assesses the psychosocial adjustment of children with chronic physical illnesses and no mental impairment. The PARS III consists of 28 items that measure psychosocial functioning in six areas: peer relations, dependency, hostility, productivity, anxiety-depression, and withdrawal.
  • Technology Acceptance Model (TAM) [ Time Frame: T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point) ]
    Technology Acceptance Model (TAM) provides a valid and reliable measure that predicts the acceptance or adoption of new technologies by end-users. TAM predicts acceptance based on the end-user's perceived usefulness (6 items) and perceived ease of use (6 items) of the technology for a specific purpose.
  • System Usability Scale (SUS) [ Time Frame: T2 (after 2-weeks home use of device 1 - primary assessment point); T3 (after 3-days short training with device 2); T4 (after 2-weeks home use of device 2 - secondary assessment point) ]
    The system usability scale (SUS) is a simple, ten-item attitude Likert scale giving a global view of subjective assessments of usability. Measurements of usability have several different aspects: effectiveness (can users successfully achieve their objectives); efficiency (how much effort and resource is expended in achieving those objectives); and satisfaction (was the experience satisfactory).

inclusion criteria:
• signed informed consent (we will expose the family the aims of our study and carefully describe the need of compliance with them)
• diagnosis of muscular dystrophy (genetic, histological and biochemical if necessary),specifically with Duchenne, Becker and Limb Girdle type 2 muscular dystrophy. No muscle biopsy will be performed, except in case there is a diagnostic need.
• being wheelchair bound
• having a scoring at the MRC scale for upper limb at the deltoid, biceps, triceps brachii muscles ranging from 2 to 4.

exclusion criteria:
• presence of additional diseases (for example: family history of mental retardation, epilepsy, cerebral palsy)
• behavioral and psychiatric disturbances (emotional problems, depression)
• absence of compliance to the study of the family and the caregivers

study contacts

sponsor: Politecnico di Milano

contacts:
Alessandra Pedrocchi (Prof.), +39022399 ext 3363, alessandra.pedrocchi@polimi.it;
Marta Gandolla (PhD), +39022399 ext 9509, marta.gandolla@polimi.it

investigators: Alessandra Pedrocchi, Prof

locations: Italy